Coreline Soft wins Japan approval, coverage for for AI-powered cancer and stroke tools

Korean medical AI company Coreline Soft said Tuesday it has renewed regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for its AVIEW platform, adding two new modules for brain and lung imaging.

The update includes NeuroCT and LungCT, which assist with detecting intracranial hemorrhage and analyzing pulmonary nodules. 

NeuroCT automatically flags and visualizes suspected bleeding areas on head and neck CT scans to support faster clinical decisions in emergency settings. LungCT offers quantitative data on the size, shape, and progression of lung nodules in chest CT scans, supporting early cancer detection and long-term monitoring.

“This latest approval and reimbursement decision allows us to offer an AI-driven diagnostic workflow optimized for Japan’s medical system, particularly in the areas of lung cancer and brain hemorrhage,” said Coreline Soft CEO Kim Jin-kook in a statement.

With the updated approval, AVIEW now qualifies for an additional reimbursement Japan offers to hospitals that adopt certified AI imaging tools. The added fee helps offset implementation costs and has become a key driver for hospital adoption, according to Tuesday's release.

Coreline plans to present its updated solutions at the Japanese Society of Thoracic Radiology (JSTR) conference on Aug. 2 at Shinagawa Intercity Hall in Tokyo.